ArticleAnnals of surgery2025
Postoperative Opioid Prescribing Among Adults with Disabilities After a Medicare Opioid Limit Policy.
Article in Annals of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prescription drug monitoring programs and perioperative opioid prescribing and adverse events.Health affairs scholar · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveDetermine whether a Medicare 7-day limit on initial opioid prescriptions (effective January 1, 2019) was associated with reductions in duration, dosage, and subsequent opioid fills among post-operative adults with disabilities.
backgroundPost-operative adults with disabilities are at increased risk for uncontrolled pain and extended opioid use.
methodsWe identified adults with disability entitlement aged 18-64 from national Medicare Advantage health plan claims data who underwent common surgeries between July 2016-June 2021. We used a repeated cross-sectional interrupted time series design to examine changes in opioid prescribing associated with the 2019 7-day limit.
resultsSample included 24,910 member-index months (mean age [SD] 55.5 [8.0] years; 14,413 [57.9%] female) representing 24,283 members. The 7-day limit was associated with an 11.8 percentage point (pp) reduction (95% CI -13.3, -10.2) in the likelihood of an initial fill >7-day supply that remained lower than predicted (-5.7 pp, 95% CI -7.6, -3.7) by June 2021. Cumulative 30-day MME was lower than predicted (-35.9 MME, 95% CI -53.7, -18.1) in January 2019 but higher than predicted by June 2021 (95.2 MME, 95% CI 56.9, 133.6). The likelihood of ≥1 fills within 30-days of the initial fill was not significantly different in January 2019 but was 6.9 pp higher (95% CI 3.1, 10.7) than predicted by June 2021.
conclusionThe 2019 Medicare 7-day limit was associated with immediate large reductions in initial opioid duration and dosage. Increased dosage observed in June 2021 may have been mediated by an increase in subsequent opioid prescriptions after the initial fill.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.